the aid library

LIST OPTIONS

Filter

5273

Sort by:

Direction:

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (127)

View PDF (102)

Policy brief on tuberculosis-associated disability

World Health Organization WHO (2023) C_WHO

People affected by impairments and disabilities associated with TB are even more likely to belong to marginalized segments of society and are more likely to have their human rights unprotected. The challenges faced by people affected by TB include the consequences of impairment and disability associ... more

Download (52)

View PDF (54)

C20 Eight Proposed Recommendations for Effective G20 Agenda on Finance and Health

Civil Society 20 (C20) - Saudi Arabia 2020 (2020) CC

As a global community of +750 representatives of the world’s civil society, the C20 official Engagement Group of the G20 is submitting a list of policy priorities for the upcoming G20 Finance Ministers & Central Bank Governors meeting on July 18th and the G20 Extraordinary Sherpa Meeting on July 2... more

Download (89)

View PDF (338)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Burkina Faso

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

Download (82)

View PDF (273)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Cameroon

Africa Center for Disease Control and Prevention (2023) CC

Download (109)

View PDF (265)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Eswatini

Africa Center for Disease Control and Prevention (2023) CC

Download (77)

View PDF (234)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Gabon

Africa Center for Disease Control and Prevention (2023) CC

Download (65)

View PDF (255)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Malawi

Africa Center for Disease Control and Prevention (2023) CC

Download (69)

View PDF (213)

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Senegal

Africa Center for Disease Control and Prevention (2023) CC

Download (65)

View PDF (90)

Rebuilding Liberia's Health System- WCO-Liberia Annual Report 2022

World Health Organisation (WHO) (2023) C_WHO

Rebuilding Liberia’s health system is crucial for improving the country’s overall health outcomes. This annual report highlights key achievements, challenges,and lessons learned in implementing programmes of technical cooperation with the Government of Liberia from January to December 2022. T... more

Download (47)

View PDF (438)

Stunting as a Risk Factor of Soil-Transmitted Helminthiasis in Children: A Literature Review

Fauziah, N.; Ar-Rizqi, M.A.; Hana, S. et al. Interdisciplinary Perspectives on Infectious Diseases (2022) CC

As a high-burden neglected tropical disease, soil-transmitted helminth (STH) infections remain a major problem in the world, especially among children under five years of age. Since young children are at high risk of being infected, STH infection can have a long-term negative impact on their life, i... more

Download (215)

View PDF (236)

Substance abuse treatmentand care for women: Case studies and lessons learned

United Nations Office on Drugs and Crime (UNODC) (2004) C1

The present booklet is about gender-responsive substance abuse treatment services for women. It is part of the United Nations Office on Drugs and Crime (UNODC) project to develop tools to support the development and improvement of substance abuse treatment services, based on evidence from the litera... more

Download (113)

View PDF (165)

Parenting programs

D. Haslam; A. Mejia; M. R. Sanders; P. J. de Vries IACAPAP (2016) C2

The importance of growing up in a nurturing and supportive family environment cannot be underestimated. Raising children in a warm, loving environment sets them on a positive developmental trajectory for later life success (Biglan et al, 2012). Conversely, children raised in homes with inconsistent ... more

Download (52)

View PDF (325)

Fexinidazole and Human African Trypanosomiasis: good news for this important neglected tropical disease

Bayão T.S., Cupertino M.C., Gomes A.P. et al Journal of the Brazilian Society of Tropical Medicine (2019) C2

Human African trypanosomiasis (HAT), or sleeping sickness, is an endemic disease in 36 sub-Saharan African countries, typically occurring in underdeveloped areas, where health systems face significant difficulties of diverse natures.

Download (41)

View PDF (242)

African Union Health Information Exchange Guidelines and Standards

Africa Center for Disease Control and Prevention (2023) CC

The application of digital health technology is growing at a rapid rate in Africa, with the goals of improving the delivery of healthcare services and more effectively reaching out to remote and underserved communities. The lack of enabling guidelines and standards across the continent, on the other... more

Download (59)

View PDF (245)

Trachoma Action Planning TAP

International Coalition for Trachoma Control ICTC (2022) CC

In 2011, ICTC developed a Trachoma Action Plan (TAP) planning guide to support national health officials in endemic countries. This resource was developed to complement the 2020 INSight roadmap by helping countries create specific national plans detailing how they will reach elimination targets in t... more